캐슬만병 치료 시장 : 치료 유형별, 약제 클래스별, 질환 유형별, 투여 경로별, 최종 사용자별, 환자 유형별 - 세계 시장 예측(2026-2032년)

The Castleman Disease Treatment Market is projected to grow by USD 624.73 million at a CAGR of 10.35% by 2032.

Castleman Disease Treatment Market Introduction

Castleman disease treatment is moving from broadly immunosuppressive care toward precision management of rare lymphoproliferative disorders. The treatment landscape spans unicentric Castleman disease, where complete surgical excision is commonly curative, and multicentric Castleman disease, where systemic therapy is required because inflammatory cytokine signaling and immune dysregulation affect multiple lymph node regions and organs.

For idiopathic multicentric Castleman disease, interleukin-6 pathway blockade remains a cornerstone of evidence-based care. Siltuximab is approved in the United States and Europe for patients with HIV-negative and HHV-8-negative multicentric Castleman disease, while tocilizumab is used in selected markets and clinical scenarios. Rituximab-based regimens are important for HHV-8-associated disease, particularly in immunocompromised populations. Corticosteroids, chemotherapy, antiviral therapy, immunomodulators, and supportive care are used according to subtype, severity, organ dysfunction, and response history.

Commercial opportunity in the Castleman disease treatment market is shaped by rarity, delayed diagnosis, limited specialist concentration, and high unmet need in relapsed, refractory, and severe inflammatory disease. Growth is supported by better diagnostic criteria, improved disease registries, expanding clinician awareness, and broader adoption of biomarker-guided therapy in hematology, oncology, immunology, and rare disease care.

Transformative Shifts in the Castleman Disease Treatment Landscape

The Castleman disease treatment landscape is being reshaped by the shift from symptom control to subtype-specific intervention. Historically, many patients received corticosteroids, chemotherapy, or empiric immunosuppression before disease subtype was fully characterized. Current practice increasingly emphasizes histopathology, HHV-8 and HIV testing, inflammatory markers, organ function assessment, and severity grading before treatment selection.

Another transformative shift is the growing role of targeted biologics. IL-6 inhibition has changed expectations for idiopathic multicentric Castleman disease by addressing a validated inflammatory driver rather than relying only on cytotoxic or broad immunosuppressive therapy. At the same time, rituximab has strengthened management of HHV-8-associated multicentric Castleman disease by targeting B-cell reservoirs involved in viral-driven pathology.

The market is also shifting toward real-world evidence generation. Because Castleman disease is rare and heterogeneous, large randomized trials are difficult to conduct. Patient registries, natural history studies, and international clinical networks are becoming essential to evaluate treatment sequencing, long-term response durability, infection risk, steroid-sparing outcomes, organ protection, and quality-of-life improvement.

Cumulative Impact of Artificial Intelligence on Castleman Disease Care

Artificial intelligence is beginning to influence Castleman disease treatment by reducing diagnostic friction in a rare condition that often mimics lymphoma, autoimmune disease, infection, or inflammatory syndromes. AI-enabled pathology image analysis can support pattern recognition in lymph node biopsies, while natural language processing can help identify possible Castleman disease cases from electronic health records based on lymphadenopathy, inflammatory markers, anemia, hypoalbuminemia, renal dysfunction, fever, and prior nondiagnostic workups.

AI is also improving research productivity. Machine learning can integrate clinical features, laboratory trends, imaging data, pathology descriptors, viral status, treatment exposures, and longitudinal outcomes to identify phenotypes more likely to respond to IL-6 blockade, rituximab, immunomodulatory therapy, or combination treatment. This is particularly valuable in idiopathic multicentric Castleman disease, where patients may show variable cytokine patterns and severity.

For industry leaders, the cumulative impact of AI will be strongest when models are paired with curated rare disease registries, validated diagnostic criteria, expert adjudication, and privacy-compliant data sharing. AI will not replace expert hematology and pathology review, but it can accelerate referral, improve trial matching, detect relapse earlier, and strengthen evidence generation for small patient populations.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

In Asia-Pacific, Castleman disease treatment is influenced by large patient pools, expanding tertiary hospital networks, and uneven access to biologics. Japan has notable clinical experience with tocilizumab in Castleman disease, while China, India, South Korea, and Australia are strengthening rare disease diagnosis through academic centers, advanced pathology, imaging capacity, and hematology referral networks. Market access varies widely across the region, making affordability, local reimbursement, biosimilar policy, and specialist concentration important factors in Castleman disease treatment adoption.

North America remains a leading region for evidence generation, specialist care, and adoption of approved biologics. The United States benefits from rare disease advocacy, academic research networks, molecular diagnostics, and access to siltuximab for eligible idiopathic multicentric Castleman disease patients, while Canada emphasizes specialist-led care within provincial reimbursement structures. Latin America, including Brazil and Mexico, shows growing clinical awareness but faces persistent challenges related to delayed diagnosis, unequal access to advanced diagnostics, fragmented referral pathways, and biologic reimbursement.

Europe benefits from centralized rare disease expertise, hematology-oncology networks, cross-border clinical collaboration, and regulatory recognition of targeted treatment options. Germany, France, Italy, Spain, and the United Kingdom are important centers for multidisciplinary care and real-world evidence generation. In the Middle East, GCC healthcare investment is improving access to specialty biologics, advanced diagnostics, and tertiary care pathways, while Africa faces the greatest barriers due to limited pathology capacity, infectious disease overlap, constrained availability of high-cost therapies, and shortages of specialized hematology services.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7 & NATO

ASEAN markets are becoming more relevant for Castleman disease treatment as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines expand oncology, immunology, pathology, and tertiary referral services. However, access to IL-6 inhibitors, rituximab-based regimens, and advanced diagnostic workups remains uneven, so regional centers of excellence, clinician education, and cross-border referral pathways are important to improve early diagnosis and treatment continuity.

The GCC is positioned for faster adoption of specialty therapies because of investment in tertiary hospitals, genomic medicine, digital health, and rare disease programs across Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman. The European Union provides a structured environment for orphan drug regulation, pharmacovigilance, health technology assessment, and cross-country clinical collaboration, supporting broader evidence development for rare hematologic and inflammatory disorders such as Castleman disease.

BRICS countries represent a high-potential but highly variable opportunity. China and India offer scale and expanding clinical research capacity, Brazil and South Africa are important regional access hubs, and Russia has established hematology expertise despite procurement and geopolitical complexities. G7 markets remain central to innovation, reimbursement debate, guideline development, rare disease advocacy, and real-world evidence generation, while NATO-aligned health systems support advanced hospital infrastructure and clinical collaboration across North America and Europe.

Key Country Insights for Castleman Disease Treatment

The United States leads Castleman disease treatment innovation through academic research, patient advocacy, access to FDA-approved siltuximab for eligible idiopathic multicentric Castleman disease, advanced pathology, and strong real-world evidence initiatives. Canada supports high-quality specialist management, although provincial reimbursement processes can influence biologic access. Mexico and Brazil are strengthening hematology networks and tertiary care capacity, but delayed referral, uneven diagnostic availability, and biologic affordability remain major market barriers.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have advanced diagnostic infrastructure, multidisciplinary hematology-oncology expertise, and established pathways for evaluating specialty therapies. Germany and France are influential in rare disease research and specialty drug assessment, while the United Kingdom contributes through national health technology evaluation and academic networks. Italy and Spain benefit from experienced hematology centers but must balance access with budget constraints. Russia maintains hematology capability, though access pathways can be affected by procurement, reimbursement, and geopolitical conditions.

In Asia-Pacific, China and India are expanding rare disease recognition, pathology capacity, and tertiary care infrastructure, creating long-term growth potential for Castleman disease treatment. Japan has established experience with IL-6 pathway inhibition and advanced immunology care, supporting evidence-based management of multicentric Castleman disease. Australia offers strong specialist referral systems and evidence-based rare disease management, while South Korea combines advanced hospital infrastructure, digital health adoption, and high-quality oncology, hematology, and immunology services.

Actionable Recommendations for Castleman Disease Treatment Industry Leaders

Industry leaders should prioritize subtype-specific education for hematologists, oncologists, immunologists, pathologists, infectious disease specialists, and surgeons. Clear differentiation between unicentric Castleman disease, idiopathic multicentric Castleman disease, and HHV-8-associated multicentric Castleman disease is essential for appropriate use of surgery, IL-6 inhibitors, rituximab-based therapy, antiviral strategies, corticosteroids, chemotherapy, and supportive care.

Manufacturers and healthcare stakeholders should invest in rare disease registries, real-world evidence platforms, and biomarker research that clarifies treatment sequencing, relapse management, and long-term outcomes. Partnerships with academic centers, referral networks, and patient organizations can improve case finding, accelerate referral, support diagnostic standardization, and strengthen clinical trial enrollment in a disease where conventional recruitment models are difficult.

Market access teams should build country-specific reimbursement strategies that demonstrate value through reduced hospitalizations, steroid-sparing benefits, organ function stabilization, durable symptom control, and improved quality of life. Organizations should also prepare for increasing payer scrutiny by generating robust response, safety, treatment persistence, and health economic evidence across diverse patient subgroups.

Research Methodology for Castleman Disease Treatment Market Insights

This executive summary is based on secondary research, clinical guideline review, regulatory intelligence, scientific literature assessment, and market access analysis relevant to Castleman disease treatment. Core inputs include peer-reviewed evidence on unicentric and multicentric Castleman disease, approved therapy labels, rare disease registry findings, hematology-oncology practice patterns, diagnostic criteria, and regional reimbursement dynamics.

The methodology emphasizes verified, data-backed insights rather than speculative market sizing. Analysis considered disease subtype, treatment mechanism, patient pathway, regional healthcare infrastructure, biologic availability, diagnostic capacity, reimbursement environment, and real-world evidence maturity. Special attention was given to IL-6 pathway inhibition, rituximab-based therapy, surgical management, corticosteroid use, chemotherapy, antiviral care, immunomodulatory therapy, and supportive treatment.

Findings were synthesized through an SEO-focused market intelligence framework designed for executive decision-making. Keywords and themes were selected to reflect high-value search intent across Castleman disease treatment, idiopathic multicentric Castleman disease therapy, IL-6 inhibitors, rare disease treatment, hematology biologics, unicentric Castleman disease surgery, and multicentric Castleman disease management.

Conclusion: Advancing Precision in Castleman Disease Treatment

Castleman disease treatment is entering a more precise and evidence-driven phase as clinicians increasingly align therapy with disease subtype, viral status, inflammatory biology, and severity. Surgical resection remains central for unicentric disease, while IL-6 pathway inhibition and rituximab-based approaches have transformed management of key multicentric disease populations.

The market outlook is supported by rising awareness, stronger rare disease networks, improved diagnostic criteria, and the growing use of real-world evidence. However, significant challenges remain, including delayed diagnosis, limited randomized trial data, uneven biologic access, and a need for better biomarkers to guide treatment sequencing, relapse monitoring, and response prediction.

Organizations that combine clinical education, registry-based evidence, AI-enabled case identification, multidisciplinary referral pathways, and region-specific access strategies will be best positioned to advance patient outcomes and capture opportunity in the global Castleman disease treatment market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Castleman Disease Treatment Market, by Treatment Type

• 7.1. Chemotherapy
• 7.2. Radiation Therapy
• 7.3. Surgical Treatment

8. Castleman Disease Treatment Market, by Drug Class

• 8.1. Siltuximab
• 8.2. Tocilizumab
• 8.3. Rituximab
• 8.4. Corticosteroids

9. Castleman Disease Treatment Market, by Disease Type

• 9.1. Unicentric Castleman Disease (UCD)
• 9.2. Oligocentric Castleman Disease (OligoCD)

10. Castleman Disease Treatment Market, by Route of Administration

• 10.1. Oral
• 10.2. Intravenous

11. Castleman Disease Treatment Market, by End User

• 11.1. Hospitals
• 11.2. Home Care Settings
• 11.3. Specialty Clinics
• 11.4. Ambulatory Surgery Centers

12. Castleman Disease Treatment Market, by Patient Type

• 12.1. Adult
• 12.2. Pediatric
• 12.3. Geriatric

13. Castleman Disease Treatment Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Castleman Disease Treatment Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Castleman Disease Treatment Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. AbbVie Inc.
• 17.2. Amgen Inc.
• 17.3. ARUP Laboratories
• 17.4. Biogen Inc.
• 17.5. Bristol-Myers Squibb Company
• 17.6. Cylene Pharmaceuticals, Inc.
• 17.7. Dr. Reddy's Laboratories
• 17.8. F. Hoffmann-La Roche Ltd.
• 17.9. Incyte Corporation
• 17.10. Johnson & Johnson Services Inc.
• 17.11. Novartis AG
• 17.12. Pfizer Inc.
• 17.13. RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.
• 17.14. Sandoz International GmbH
• 17.15. Swedish Orphan Biovitrum AB
• 17.16. Takeda Pharmaceutical Company Limited